Revised <scp>MALT‐IPI</scp> : A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma-Reference-Cited by-同舟云学术

Revised MALT‐IPI : A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

Published:2022-09-19 Issue:12 Volume:97 Page:1529-1537
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Alderuccio Juan Pablo¹^ORCID,Reis Isildinha M.²³,Habermann Thomas M.⁴^ORCID,Link Brian K.⁵,Thieblemont Catherine⁶,Conconi Annarita⁷,Larson Melissa C.⁸,Cascione Luciano⁹,Zhao Wei³,Cerhan James R.⁸^ORCID,Zucca Emanuele⁹¹⁰¹¹,Lossos Izidore S.¹^ORCID

Affiliation:

1. Division of Hematology Sylvester Comprehensive Cancer Center Miami Florida USA

2. Department of Public Health Sciences University of Miami Miller School of Medicine Miami Florida USA

3. Biostatistics and Bioinformatics Shared Resource Sylvester Comprehensive Cancer Center Miami Florida USA

4. Division of Hematology Mayo Clinic Rochester Minnesota USA

5. Division of Hematology, Oncology and Bone and Marrow Transplantation University of Iowa Iowa City Iowa USA

6. APHP, Hôpital Saint‐Louis, Service d'hémato‐oncologie DMU DHI, Université de Paris Paris France

7. Division of Hematology Ospedale degli Infermi Biella Italy

8. Department of Quantitative Health Sciences Mayo Clinic Rochester Minnesota USA

9. Clinic of Medical Oncology, Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

10. Institute of Oncology Research, Faculty of Biomedical Sciences Università della Svizzera Italiana Bellinzona Switzerland

11. Department of Medical Oncology Bern University Hospital and University of Bern Bern Switzerland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26715

Reference31 articles.

1. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance

2. Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States

3. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma

4. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study;The Lancet Rheumatology;2024-08

2. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment;eClinicalMedicine;2024-06

3. Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2024-06

4. Advances in the treatment of relapsed/refractory marginal zone lymphoma;Frontiers in Oncology;2024-01-25

5. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study;Blood Advances;2023-11-15